Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cetuximab
/ administration & dosage
Chemotherapy, Adjuvant
/ mortality
Colonic Neoplasms
/ drug therapy
Female
Fluorouracil
/ administration & dosage
Follow-Up Studies
Humans
Leucovorin
/ administration & dosage
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Prognosis
Prospective Studies
Retrospective Studies
Survival Rate
Young Adult
ras Proteins
/ genetics
Adjuvant therapy
Colon cancer
Deficient mismatch repair
Microsatellite instability
Prognosis
Recurrence
Risk groups
Stage III
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
01
07
2020
revised:
15
10
2020
accepted:
07
11
2020
pubmed:
21
12
2020
medline:
18
9
2021
entrez:
20
12
2020
Statut:
ppublish
Résumé
Stratification of patients with stage III colon cancer into low (T Stage III colon cancer (N = 5337) patients from two adjuvant trials of FOLFOX ± cetuximab [N0147 (Alliance), PETACC-8] were risk grouped, then subgrouped by clinical features and molecular variables [KRAS and BRAF/mismatch repair (MMR) combined variable]. Distributions of disease-free survival (DFS), overall survival (OS), and survival after recurrence (SAR) were estimated. In multivariable Cox models, backward elimination was performed for analysis of candidate predictors of outcomes. Relative contributions of model-selected variables to outcomes by risk group were calculated using χ2. Among low risk tumours, mutant KRAS and male gender were significantly associated with poorer OS multivariately. In high risk tumours, significantly poorer OS was observed for right sidedness and for mutant KRAS and BRAF Sidedness and BRAF/MMR contributed the most to survival outcomes among high risk tumours and should be interpreted in the context of risk group.
Sections du résumé
BACKGROUND
Stratification of patients with stage III colon cancer into low (T
MATERIALS & METHODS
Stage III colon cancer (N = 5337) patients from two adjuvant trials of FOLFOX ± cetuximab [N0147 (Alliance), PETACC-8] were risk grouped, then subgrouped by clinical features and molecular variables [KRAS and BRAF/mismatch repair (MMR) combined variable]. Distributions of disease-free survival (DFS), overall survival (OS), and survival after recurrence (SAR) were estimated. In multivariable Cox models, backward elimination was performed for analysis of candidate predictors of outcomes. Relative contributions of model-selected variables to outcomes by risk group were calculated using χ2.
RESULTS
Among low risk tumours, mutant KRAS and male gender were significantly associated with poorer OS multivariately. In high risk tumours, significantly poorer OS was observed for right sidedness and for mutant KRAS and BRAF
CONCLUSION
Sidedness and BRAF/MMR contributed the most to survival outcomes among high risk tumours and should be interpreted in the context of risk group.
Identifiants
pubmed: 33341444
pii: S0959-8049(20)31348-4
doi: 10.1016/j.ejca.2020.11.016
pmc: PMC7855426
mid: NIHMS1658118
pii:
doi:
Substances chimiques
ras Proteins
EC 3.6.5.2
Cetuximab
PQX0D8J21J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-112Subventions
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210509
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA232760
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None declared.
Références
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Clin Cancer Res. 2009 Oct 15;15(20):6391-7
pubmed: 19789331
JAMA Oncol. 2015 Aug;1(5):653-61
pubmed: 26181352
PLoS One. 2013 Jul 05;8(7):e68077
pubmed: 23861851
J Med Genet. 2004 Sep;41(9):664-8
pubmed: 15342696
J Clin Oncol. 2015 Dec 10;33(35):4176-87
pubmed: 26527776
N Engl J Med. 2018 Mar 29;378(13):1177-1188
pubmed: 29590544
J Clin Pathol. 2018 Jan;71(1):46-51
pubmed: 28667193
Cancer. 2014 Aug 1;120(15):2316-24
pubmed: 24737664
JAMA Oncol. 2016 May 1;2(5):643-653
pubmed: 26768652
Lancet Oncol. 2014 Jul;15(8):862-73
pubmed: 24928083
Clin Cancer Res. 2017 Aug 15;23(16):4753-4760
pubmed: 28446505
Clin Gastroenterol Hepatol. 2019 Feb;17(3):455-462.e6
pubmed: 29660527
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Gut. 2016 Dec;65(12):1973-1980
pubmed: 26311717
Cancer. 2011 Oct 15;117(20):4623-32
pubmed: 21456008
Clin Cancer Res. 2014 Jun 1;20(11):3033-43
pubmed: 24687927
Ann Oncol. 2020 Oct;31(10):1291-1305
pubmed: 32702383
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
Clin Transl Gastroenterol. 2016 Nov 3;7(11):e200
pubmed: 27811909
Clin Cancer Res. 2018 Mar 1;24(5):1062-1072
pubmed: 29180604
JAMA Oncol. 2017 Apr 1;3(4):472-480
pubmed: 28006055
Langenbecks Arch Surg. 2020 Feb;405(1):71-80
pubmed: 32002628
JAMA. 2012 Apr 4;307(13):1383-93
pubmed: 22474202
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15
pubmed: 18990764
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110